Characterization of Protein Therapeutics using Mass Spectrometry

Dr. Guodong Chen has extensive pharmaceutical research experience in major pharmaceutical companies, including Eli Lilly, Schering-Plough (now Merck) and Bristol-Myers Squibb. He is currently heading a mass spectrometry group at Bristol-Myers Squibb's Princeton site, providing mass spectrometric/analytical support to drug discovery and development programs in small molecule pharmaceuticals and biologics. He has over 45 research publications in peer-reviewed journals and 9 book chapters covering the broad area of mass spectrometry and analytical sciences. He has co-edited two books: "Characterization of Impurities and Degradants Using Mass Spectrometry" and "Mass Spectrometry of Proteins/Peptides in Drug Discovery" (respectively 2010 and forthcoming). He is a short course instructor for two short courses on "LC/MS: Theory, Instruments and Applications" and "Practical Solutions to Characterization of Protein Therapeutics Using Mass Spectrometry" at Eastern Analytical Symposium.

• Characterization of Protein Therapeutics by Mass Spectrometry: Recent Developments and Future Directions.- The Use of Mass Spectrometry to Characterize the Metabolism of Peptide Therapeutics.- Quantitative Analysis of Biologics Using Mass Spectrometry.- Maximizing Structural Information from Whole Protein Tandem Mass Spectrometry.- Disulfide Linkages of an Albumin Fusion Protein.- Detailed Structural Characterization of Monoclonal Antibodies.- Application of Protein Mass Spectrometry in Impurity and Degradant Characterization.- Mass Spectrometry Methods to Analyze Higher Order Structure of Protein Therapeutics by Chemical Footprinting.- Aglycosylations Alters Protein Conformation in Antibodies Engineered with Specific Effector Functions Using HDX-MS.- Characterizing Biotherapeutic Protein 3D Structures by Electrospray Ion-Mobility Mass Spectrometry.- Oxford University, Characterization of Assemblies of Proteins by Mass Spectrometry.